09 Nov 2020
Beijing Wantai Biological Pharmacy Enterprise Co Ltd plans to start a mid-stage clinical trial this month of a nasal spray coronavirus vaccine in China, clinical trial registry data showed.
An alternative to the common injection in the arm, the spray vaccine can trigger specific immune responses in airways by mimicking the natural infection of a respiratory virus, its researchers have said.
The candidate uses a weakened influenza virus to ferry a genetic snippet of coronavirus protein. The Phase 2 study will also evaluate how pre-existing antibodies against a specific type of flu virus in healthy people affect the vaccine.